Featured Research

from universities, journals, and other organizations

Tumor-reactive T Cells Boosted By Hematopoietic Stem Cell Transplantation

Date:
February 5, 2007
Source:
Journal of Clinical Investigation
Summary:
Although treatment regimens involving the infusion of tumor-reactive T cells into patients with skin cancer (melanoma) have shown clinical benefit, there is plenty of room to improve the protocols to increase therapeutic benefit.

Although treatment regimens involving the infusion of tumor-reactive T cells into patients with skin cancer (melanoma) have shown clinical benefit, there is plenty of room to improve the protocols to increase therapeutic benefit. Regimens currently being investigated in humans involve pre-treatment with agents that transiently decrease the number of immune cells (and that are known as nonmyeloablative agents), enabling the subsequently infused tumor-reactive T cells to increase in number in vivo.

Related Articles


In a study that appears in the February issue of the Journal of Clinical Investigation, Nicholas Restifo and colleagues from the National Institutes of Health show that in mice, pre-treatment with more intense immune cell–depleting strategies (known as myeloablative strategies) and a hematopoietic stem cell (HSC) transplantation enabled infused tumor-reactive CD8+ T cells to increase in number more than pre-treatment with nonmyeloablative agents.

Importantly, this increased expansion of the CD8+ T cell population correlated with increased tumor regression. Further analysis showed that it was the HSC transplantation, and not the increased immune cell depletion, that made the myeloablative agents more effective at inducing the infused tumor-reactive T cell population to expand and that it was the effector CD8+ T cell population, rather than the naοve T cell population, that expanded.

This study has important implications for the future development of treatment regimens involving the infusion of tumor-reactive T cells into patients with melanoma.

In an accompanying commentary, Claudio Anasetti and James J. Mulι from the H. Lee Moffitt Comprehensive Cancer Center, Tampa, discuss the issues that are raised by these data and the implications that these issues have for the development of cell-based immunotherapies for cancer.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Cite This Page:

Journal of Clinical Investigation. "Tumor-reactive T Cells Boosted By Hematopoietic Stem Cell Transplantation." ScienceDaily. ScienceDaily, 5 February 2007. <www.sciencedaily.com/releases/2007/02/070204112030.htm>.
Journal of Clinical Investigation. (2007, February 5). Tumor-reactive T Cells Boosted By Hematopoietic Stem Cell Transplantation. ScienceDaily. Retrieved March 3, 2015 from www.sciencedaily.com/releases/2007/02/070204112030.htm
Journal of Clinical Investigation. "Tumor-reactive T Cells Boosted By Hematopoietic Stem Cell Transplantation." ScienceDaily. www.sciencedaily.com/releases/2007/02/070204112030.htm (accessed March 3, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 3, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Treadmill Test Can Predict Chance Of Death Within A Decade

Treadmill Test Can Predict Chance Of Death Within A Decade

Newsy (Mar. 2, 2015) — Johns Hopkins researchers analyzed 58,000 heart stress tests to come up with a formula that predicts a person&apos;s chances of dying in the next decade. Video provided by Newsy
Powered by NewsLook.com
Going Gluten-Free Could Get You A Tax Break

Going Gluten-Free Could Get You A Tax Break

Newsy (Mar. 2, 2015) — If a doctor advises you to remove gluten from your diet, you could get a tax deduction on the amount you spend on gluten-free foods. Video provided by Newsy
Powered by NewsLook.com
GlaxoSmithKline and Novartis Try Swapping Success

GlaxoSmithKline and Novartis Try Swapping Success

Reuters - Business Video Online (Mar. 2, 2015) — GlaxoSmithKline and Novartis have completed a series of asset swaps worth more than $20 billion. As Grace Pascoe reports they say the deal will reshape both drugmakers. Video provided by Reuters
Powered by NewsLook.com
How Can West Africa Rebuild After Ebola?

How Can West Africa Rebuild After Ebola?

Reuters - Business Video Online (Mar. 2, 2015) — How best to rebuild the three West African countries struggling with Ebola will be discussed in Brussels this week. As Hayley Platt reports Sierra Leone has the toughest job ahead - its once thriving economy has been ravaged by the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins